Mizuho Securities Sees More Upside in Arcus Biosciences (RCUS) on Gilead Opt-In
Tweet Send to a Friend
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating and $51.00 price target on Arcus Biosciences (NYSE: RCUS) after Gilead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
